Rafat Abonour, MD
Indiana University Simon Cancer Center
Indianapolis, IN, USA
Phase 3 trials demonstrated maintenance therapy after autologous stem cell transplant (ASCT) extended time to progression, progression-free survival, and in some cases overall survival for patients (pts) with multiple myeloma (MM) (Sonneveld, 2012; McCarthy, 2012; Attal, 2012; Palumbo, 2014; Attal, 2016). Maintenance treatment until progression has the potential to adversely impact health-related quality of life (HRQoL). Few HRQoL analyses have been published in MM, especially with regard to maintenance therapy after ASCT. Connect® MM is the first and largest multicenter, US-based, prospective observational cohort study designed to characterize treatment patterns and outcomes for pts with newly diagnosed MM (NDMM). This analysis evaluated HRQoL of pts who received Any maintenance therapy, lenalidomide (LEN) only, or No maintenance post-ASCT.
Please subscribe to our channel!
Subscribe to International Myeloma Foundation: http://bit.ly/XlUtPE
Visit our website at: http://www.myeloma.org
Find us online:
IMF on twitter: @IMFMyeloma (http://twitter.com/imfmyeloma)
Dr. Durie on twitter: @BrianDurieMD (http://twitter.com/brianduriemd)
Support the IMF! http://bit.ly/WskQHC
Nonprofits & Activism
Standard YouTube License